Christopher Anthony Carlos, MD

Offices

5 locations · UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco

Looking this up.

Hospitals listed: 052728 · UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Carlos’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Imperial Courage Plan (HMO)	Imperial Health Plan of California, Inc.	Listed	Sep 1, 2026
Imperial Dynamic Plan (HMO)	Imperial Health Plan of California, Inc.	Listed	Sep 1, 2026
Imperial Senior Value (HMO C-SNP)	Imperial Health Plan of California, Inc.	Listed	Sep 1, 2026

California Medical Board record

Licence A134161 · Current

Licensed to practise in California · since 2015 · expires 2028-05-31 · Case Western Reserve University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

American Board of Internal Medicine - Internal Medicine
American Board of Internal Medicine - Nephrology

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 75.0 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at UCSF Medical Center

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	4.9 (3.79 to 6.02) · 7,590 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	12.8 (11.3 to 14.4) · 2,019 cases	Worse	Jan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	139.4 (110.22 to 168.58) · 452 cases	Better	Jul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.622	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.626	Better	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.491	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.8 (0.7 to 1) · 2,336 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.24 (0.58 to 1.9) · 4,689 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	1.05 (0.89 to 1.2)	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.9 · 89 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	7.5 · 85 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	10.1 · 132 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.6 · 454 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 618 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	9.6 · 380 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.7 · 5,000 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.22 (0.06 to 0.38) · 15,965 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.2 (0.05 to 0.35) · 17,859 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.85 (0 to 1.83) · 4,184 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2 (1.1 to 2.9) · 6,516 cases	No different	Jul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths	7.35 (4.49 to 10.21) · 3,989 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5 (3.22 to 6.77) · 4,087 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.95 (0.74 to 3.15) · 2,034 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.95 (0.63 to 1.28) · 15,431 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	4 · 399 cases	None	Apr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.899	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.689	No different	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	1.224	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16 · 156 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20 · 564 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	60.3 · 160 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-9.7 · 550 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	44.1 · 660 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.8 · 667 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.7 (4.8 to 6.7) · 2,019 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	6 · 421 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	10.5 · 53 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	20 · 107 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	13.9 (11.3 to 17.1) · 3,247 cases	No different	Jan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at UCSF Medical Center

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at UCSF Medical Center

Room was "always" clean	71%
Nurses "always" communicated well	80%
Doctors "always" communicated well	80%
Staff "always" explained	61%
Yes, staff "did" give patients this information	88%
Yes, staff "did" give patients information about help after discharge	87%
Doctors "always" explained things so they could understand	74%
Doctors "always" listened carefully	78%
Doctors "always" treated them with courtesy and respect	86%
Patients who gave a rating of "9" or "10" (high)	76%
Staff "always" explained new medications	75%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	78%
Nurses "always" treated them with courtesy and respect	86%
"Always" quiet at night	50%
"YES", patients would definitely recommend the hospital	81%
Staff "always" explained possible side effects	46%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$69,569

Medicare paid this office $69,569 for 190 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	62	$12,560	$113
Return visit (30+ min)	73	$7,843	$73
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	25	$6,891	$101
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	116	$2,837	$14
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	16	$2,311	$68

See all 10 services

Sort by

Every Original Medicare service billed

Long return visit (40+ min)	62	$12,560	$113
Return visit (30+ min)	73	$7,843	$73
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	25	$6,891	$101
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	116	$2,837	$14
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	16	$2,311	$68
New patient visit (60+ min)	15	$2,260	$151
Hemodialysis procedure with physician evaluation	19	$2,064	$63
Initial hospital care with moderate level of medical decision making at least 75 minutes	14	$1,987	$142
Telephone medical discussion with physician, 11-20 minutes	17	$821	$43
Telephone medical discussion with physician, 5-10 minutes	11	$311	$26

Who their Medicare patients are

190 Original Medicare patients in 2024. Average age 72 · Under 65 17% · 85 and older 13% · Women 47% · Also on Medicaid 40% · Health risk score 4.20. Sicker patients than 9 in 10 peers; the typical internal medicine clinician is at 1.76.

Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 54% · Heart failure 43% · Coronary heart disease 42% · Atrial fibrillation 26% · Depression 22% · Cancer 20% · COPD 18% · Stroke 15% · Dementia 14%.

The office billed $437,358, Medicare allowed $92,878 and paid $69,569; for 985 services of 25 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	190	985	72	4.20	$437,358	$69,569
2023	228	901	72	4.41	$536,312	$91,124
2022	328	2,034	71	3.87	$785,942	$131,690
2021	317	1,297	69	4.75	$687,157	$117,481
2020	271	1,166	71	4.73	$605,205	$94,224
2019	259	809	69	4.49	$490,008	$72,051
2018	77	126	72	2.57	$97,025	$12,584

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 9 services

Sort by

Original Medicare services billed in 2023

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	67	$18,674	$107
Dialysis services, 2-3 physician visits per month (20 years or older)	12	$18,605	$270
Long return visit (40+ min)	60	$13,842	$118
Return visit (30+ min)	66	$7,799	$78
Dialysis procedure including 1 evaluation	17	$5,909	$79
Initial hospital care with moderate level of medical decision making at least 75 minutes	33	$5,319	$152
Hemodialysis procedure with physician evaluation	33	$4,045	$64
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	14	$1,499	$71
Telephone medical discussion with physician, 11-20 minutes	13	$806	$58

2022: 13 services

Sort by

Original Medicare services billed in 2022

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	120	$36,464	$91
Long return visit (40+ min)	72	$15,728	$115
Dialysis services, 2-3 physician visits per month (20 years or older)	16	$13,750	$270
Return visit (30+ min)	96	$10,931	$81
Dialysis services, 1 physician visit per month (20 years or older)	16	$10,462	$187
Initial hospital care with moderate level of medical decision making at least 75 minutes	51	$8,988	$173
Dialysis procedure including 1 evaluation	25	$6,768	$79
Hemodialysis procedure with physician evaluation	33	$3,372	$65
New patient visit (60+ min)	18	$2,443	$136
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	14	$1,555	$111
New patient visit (45+ min)	13	$1,543	$119
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	17	$1,269	$63
Telephone medical discussion with physician, 11-20 minutes	13	$710	$47

2021: 10 services

Sort by

Original Medicare services billed in 2021

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	120	$28,000	$92
Long return visit (40+ min)	95	$22,000	$117
Return visit (30+ min)	71	$9,113	$84
Dialysis services, 1 physician visit per month (20 years or older)	14	$8,661	$188
Dialysis services, 2-3 physician visits per month (20 years or older)	11	$7,894	$272
Dialysis procedure including 1 evaluation	24	$7,818	$79
Initial hospital care with moderate level of medical decision making at least 75 minutes	42	$7,517	$179
Hemodialysis procedure with physician evaluation	60	$7,379	$65
New patient visit (60+ min)	22	$3,573	$162
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	22	$2,788	$121

2020: 10 services

Sort by

Original Medicare services billed in 2020

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	98	$24,337	$95
Long return visit (40+ min)	99	$16,017	$94
Hemodialysis procedure with physician evaluation	65	$8,806	$66
Initial hospital care with moderate level of medical decision making at least 75 minutes	37	$6,777	$183
Dialysis procedure including 1 evaluation	25	$5,303	$82
Return visit (30+ min)	49	$4,777	$69
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	20	$2,418	$121
New patient visit (60+ min)	13	$1,977	$152
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	16	$1,290	$64
Telephone medical discussion with physician, 21-30 minutes	13	$1,284	$68

2019: 7 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	103	$20,241	$92
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	90	$18,304	$92
Hemodialysis procedure with physician evaluation	61	$8,287	$65
Dialysis procedure including 1 evaluation	25	$7,187	$77
Initial hospital care with moderate level of medical decision making at least 75 minutes	33	$6,264	$179
New patient visit (60+ min)	13	$1,931	$149
New patient visit (45+ min)	16	$1,820	$114

2018: 2 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	44	$6,525	$97
Return visit (30+ min)	15	$1,048	$70

Medicaid work

$6,188 in 2023

Medicaid paid $6,188 for 54 billed services this clinician did in 2023, up to 14 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2023

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	54	$6,188

Sort by

Medicaid work by year

2023	54	1	14	$6,188
2022	116	1	14	$7,742
2021	74	2	14	$4,519
2020	168	2	20	$10,651
2019	115	2	19	$7,973

See the largest Medicaid services in earlier years

2022

Sort by

Largest Medicaid services in 2022

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	116	$7,742

2021

Sort by

Largest Medicaid services in 2021

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	47	$2,556
Long return visit (40+ min)	27	$1,962

2020

Sort by

Largest Medicaid services in 2020

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	136	$8,537
Hemodialysis procedure with single evaluation by a physician or other qualified health care professional	32	$2,115

2019

Sort by

Largest Medicaid services in 2019

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	74	$5,005
Long return visit (40+ min)	41	$2,968

Drugs they prescribed that Part D paid

$185,831

Pharmacies billed $185,831 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 771) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.

627 generic and 144 brand-name prescriptions · $185,831 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Jardiance	38	$50,074	$1,318
Farxiga	37	$33,812	$914
Ozempic	19	$29,502	$1,553
Lokelma	14	$18,589	$1,328
Sevelamer Carbonate	34	$5,664	$167

See all 23 drugs

Sort by

Every Part D drug this clinician prescribed

Jardiance	38	$50,074	$1,318
Farxiga	37	$33,812	$914
Ozempic	19	$29,502	$1,553
Lokelma	14	$18,589	$1,328
Sevelamer Carbonate	34	$5,664	$167
Eplerenone	26	$3,409	$131
Calcium Acetate	17	$1,233	$73
Bumetanide	16	$1,226	$77
Losartan	104	$1,092	$11
Nifedipine Er	12	$563	$47
Benazepril	14	$501	$36
Chlorthalidone	29	$436	$15
Furosemide	35	$410	$12
Amlodipine Besylate	59	$338	$6
Labetalol	11	$331	$30
Prednisone	16	$329	$21
Olmesartan Medoxomil	13	$265	$20
Spironolactone	17	$221	$13
Carvedilol	22	$176	$8
Atorvastatin	20	$129	$6
Lisinopril	21	$104	$5
Hydrochlorothiazide	24	$62	$3
Allopurinol	25	$49	$2

Year by year

Sort by

Part D prescribing by year

2024	771	119	0% (0)	19%	$185,831
2023	788	128	0% (0)	None	$217,371
2022	1,008	145	0% (0)	26%	$295,810
2021	841	116	0% (0)	27%	$231,852
2020	596	84	0% (0)	None	$152,120
2019	382	70	0% (0)	20%	$27,393
2018	91	38	None	14%	$2,262
2017	63	16	0% (0)	None	$5,368
2016	14	None	0% (0)	0%	$140

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 21 drugs

Sort by

Part D drugs prescribed in 2023

Jardiance	27	$36,900	$1,367
Farxiga	25	$36,421	$1,457
Renvela	20	$32,806	$1,640
Lokelma	18	$20,777	$1,154
Veltassa	16	$16,976	$1,061
Sevelamer Carbonate	19	$9,812	$516
Losartan	124	$2,321	$19
Eplerenone	27	$1,799	$67
Bumetanide	23	$997	$43
Amlodipine Besylate	54	$754	$14
Irbesartan	11	$753	$68
Chlorthalidone	35	$688	$20
Furosemide	49	$583	$12
Benazepril	20	$567	$28
Carvedilol	33	$548	$17
Lisinopril	30	$386	$13
Metoprolol	15	$291	$19
Atorvastatin	14	$245	$17
Spironolactone	19	$230	$12
Allopurinol	14	$190	$14
Hydrochlorothiazide	22	$181	$8

2022: 26 drugs

Sort by

Part D drugs prescribed in 2022

Lokelma	54	$51,304	$950
Farxiga	43	$37,752	$878
Veltassa	33	$33,758	$1,023
Renvela	25	$29,463	$1,179
Jardiance	15	$26,393	$1,760
Velphoro	16	$25,769	$1,611
Aranesp	11	$15,704	$1,428
Sevelamer Carbonate	20	$6,314	$316
Eplerenone	23	$4,639	$202
Bumetanide	42	$2,908	$69
Calcium Acetate	14	$2,632	$188
Losartan	126	$1,807	$14
Labetalol	22	$1,445	$66
Chlorthalidone	31	$899	$29
Nifedipine Er	13	$755	$58
Carvedilol	34	$729	$21
Furosemide	65	$715	$11
Amlodipine Besylate	60	$468	$8
Spironolactone	28	$387	$14
Metoprolol	20	$348	$17
Allopurinol	14	$313	$22
Lisinopril	38	$207	$5
Benazepril	13	$184	$14
Atorvastatin	11	$161	$15
Hydrochlorothiazide	31	$139	$4
Tamsulosin	11	$131	$12

2021: 25 drugs

Sort by

Part D drugs prescribed in 2021

Velphoro	24	$49,012	$2,042
Lokelma	33	$30,000	$909
Renvela	17	$27,134	$1,596
Procrit	12	$24,730	$2,061
Veltassa	15	$17,731	$1,182
Aranesp	16	$16,386	$1,024
Jardiance	12	$15,059	$1,255
Farxiga	21	$11,735	$559
Sevelamer Carbonate	20	$8,088	$404
Bumetanide	40	$3,857	$96
Eplerenone	12	$1,671	$139
Losartan	111	$1,528	$14
Labetalol	20	$1,242	$62
Chlorthalidone	21	$867	$41
Nifedipine Er	16	$865	$54
Furosemide	59	$581	$10
Amlodipine Besylate	53	$484	$9
Benazepril	20	$336	$17
Hydralazine	17	$292	$17
Atorvastatin	27	$272	$10
Lisinopril	36	$254	$7
Spironolactone	35	$226	$6
Allopurinol	11	$225	$20
Carvedilol	21	$209	$10
Hydrochlorothiazide	16	$120	$7

2020: 18 drugs

Sort by

Part D drugs prescribed in 2020

Velphoro	18	$39,073	$2,171
Renvela	13	$23,268	$1,790
Aranesp	26	$16,992	$654
Lokelma	24	$16,271	$678
Retacrit	11	$8,328	$757
Sevelamer Carbonate	23	$4,038	$176
Bumetanide	17	$1,776	$104
Nifedipine Er	18	$1,738	$97
Losartan	62	$750	$12
Labetalol	17	$715	$42
Chlorthalidone	18	$482	$27
Furosemide	55	$434	$8
Amlodipine Besylate	53	$385	$7
Calcitriol	13	$381	$29
Benazepril	12	$187	$16
Carvedilol	13	$154	$12
Lisinopril	18	$111	$6
Tamsulosin	11	$81	$7

2019: 10 drugs

Sort by

Part D drugs prescribed in 2019

Bumetanide	12	$1,429	$119
Nifedipine Er	13	$1,008	$78
Labetalol	11	$587	$53
Furosemide	67	$478	$7
Losartan	40	$372	$9
Amlodipine Besylate	46	$334	$7
Calcitriol	11	$250	$23
Carvedilol	16	$141	$9
Benazepril	12	$116	$10
Lisinopril	16	$98	$6

2018: 2 drugs

Sort by

Part D drugs prescribed in 2018

Losartan	18	$96	$5
Furosemide	14	$95	$7

2017: 1 drug

Sort by

Part D drugs prescribed in 2017

Calcitriol	11	$289	$26

Money from drug and device companies

$276 in 2025

Sort by

Industry payments by year

2025	1	11	None	$276
2024	2	8	None	$162
2023	2	6	$2,125	$4,144
2019	2	2	None	$197

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Novartis Pharmaceuticals	Fabhalta	$276	11 payments Meals for Fabhalta · 2025-12-09 · $27 Meals for Fabhalta · 2025-08-21 · $27 Meals for Fabhalta · 2025-08-21 · $27 Meals for Fabhalta · 2025-07-29 · $32 Meals for Fabhalta · 2025-07-29 · $32 Meals for Fabhalta · 2025-05-30 · $26 Meals for Fabhalta · 2025-05-06 · $11 Meals for Fabhalta · 2025-04-16 · $21 Meals for Fabhalta · 2025-03-20 · $28 Meals for Fabhalta · 2025-02-13 · $32 Meals for Fabhalta · 2025-01-09 · $12

See all 11 published payments

Sort by

Every published payment

Novartis Pharmaceuticals	Meals · 2025-12-09	Fabhalta	$27
Novartis Pharmaceuticals	Meals · 2025-08-21	Fabhalta	$27
Novartis Pharmaceuticals	Meals · 2025-08-21	Fabhalta	$27
Novartis Pharmaceuticals	Meals · 2025-07-29	Fabhalta	$32
Novartis Pharmaceuticals	Meals · 2025-07-29	Fabhalta	$32
Novartis Pharmaceuticals	Meals · 2025-05-30	Fabhalta	$26
Novartis Pharmaceuticals	Meals · 2025-05-06	Fabhalta	$11
Novartis Pharmaceuticals	Meals · 2025-04-16	Fabhalta	$21
Novartis Pharmaceuticals	Meals · 2025-03-20	Fabhalta	$28
Novartis Pharmaceuticals	Meals · 2025-02-13	Fabhalta	$32
Novartis Pharmaceuticals	Meals · 2025-01-09	Fabhalta	$12

See earlier years (2024, 2023, 2019)

2024: $162

Sort by

Payments by company in 2024

Novartis Pharmaceuticals	Fabhalta	$155	6 payments Meals for Fabhalta · 2024-11-22 · $31 Meals for Fabhalta · 2024-10-31 · $8 Meals · 2024-09-26 · $30 Meals · 2024-08-22 · $30 Meals · 2024-04-19 · $28 Meals · 2024-03-15 · $30
Travere Therapeutics	None	$6	2 payments Education · 2024-05-01 · $3 Education · 2024-03-29 · $3

2023: $4,144

Sort by

Payments by company in 2023

Calliditas Therapeutics US	Tarpeyo	$4,138	4 payments Meals for Tarpeyo · 2023-07-27 · $32 Consulting for Tarpeyo · 2023-06-23 · $2,125 Travel for Tarpeyo · 2023-06-23 · $1,934 Meals for Tarpeyo · 2023-06-22 · $47
Travere Therapeutics	None	$6	2 payments Education · 2023-12-15 · $3 Education · 2023-12-11 · $3

2019: $197

Sort by

Payments by company in 2019

Alexion Pharmaceuticals	Soliris	$99	1 payment Education for Soliris · 2019-08-15 · $99
Relypsa	Veltassa	$98	1 payment Meals for Veltassa · 2019-11-09 · $98

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Genentech, Inc. · Crovalimab in Ahus Adult and Adolescent Patients · 2023	Their institution	$40,771
Genentech, Inc. · Crovalimab in Ahus Adult and Adolescent Patients · 2025	Their institution	$39,579
Genentech, Inc. · Crovalimab in Ahus Adult and Adolescent Patients · 2024	Their institution	$33,223
Novartis Pharmaceuticals Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Bion-1301 in Adults With Iga Nephropathy (the Beyond Study) · 2025	Their institution	$8,412

Professional record

NPI: 1457693921
Licence: CA A134161California A134161: Current · expires 2028-05-31
Group: UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: Yes
Taxonomy: Federal specialty code 207RN0300X (207RN0300X)
Mailing address: 533 Parnassus Ave, San Francisco, CA, 94143
NPI first listed: 2013-03-22
NPI last updated: 2019-10-01

This is when the NPI record was last certified, not a medical board exam.